• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

全球范围内 SARS-CoV-2 血清流行率：一项更新的系统评价和荟萃分析。

SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis.

机构信息

Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran.

Department of Epidemiology and Biostatistics, Faculty of Medicine, Kurdistan University of Medical Science, Sanandaj, Iran.

出版信息

Eur J Med Res. 2022 Jun 2;27(1):81. doi: 10.1186/s40001-022-00710-2.

DOI:10.1186/s40001-022-00710-2
PMID:35655237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9160514/
Abstract

BACKGROUND

Covid-19 has been one of the major concerns around the world in the last 2 years. One of the challenges of this disease has been to determine its prevalence. Conflicting results of the serology test in Covid explored the need for an updated meta-analysis on this issue. Thus, this systematic review aimed to estimate the prevalence of global SARS-CoV-2 serology in different populations and geographical areas.

METHODS

To identify studies evaluating the seroprevalence of SARS-CoV-2, a comprehensive literature search was performed from international databases, including Medline (PubMed), Web of Sciences, Scopus, EMBASE, and CINHAL.

RESULTS

In this meta-analysis, the results showed that SARS-CoV-2 seroprevalence is between 3 and 15% worldwide. In Eastern Mediterranean, the pooled estimate of seroprevalence SARS-CoV-2 was 15% (CI 95% 5-29%), and in Africa, the pooled estimate was 6% (CI 95% 1-13%). In America, the pooled estimate was 8% (CI 95% 6-11%), and in Europe, the pooled estimate was 5% (CI 95% 4-6%). Also the last region, Western Pacific, the pooled estimate was 3% (CI 95% 2-4%). Besides, we analyzed three of these areas separately. This analysis estimated the prevalence in subgroups such as study population, diagnostic methods, sampling methods, time, perspective, and type of the study.

CONCLUSION

The present meta-analysis showed that the seroprevalence of SARS-CoV-2 has been between 3 and 15% worldwide. Even considering the low estimate of this rate and the increasing vaccination in the world, many people are still susceptible to SARS-CoV-2.

摘要

背景

在过去的 2 年中，Covid-19 一直是全球关注的主要问题之一。该疾病的挑战之一是确定其流行率。对 Covid 血清学检测的相互矛盾的结果探索了对此问题进行更新的荟萃分析的必要性。因此，本系统评价旨在估计全球不同人群和地理区域 SARS-CoV-2 血清学的流行率。

方法

为了确定评估 SARS-CoV-2 血清流行率的研究，从包括 Medline（PubMed）、Web of Sciences、Scopus、EMBASE 和 CINHAL 在内的国际数据库中进行了全面的文献检索。

结果

在这项荟萃分析中，结果表明全球范围内 SARS-CoV-2 的血清流行率在 3%至 15%之间。在地中海东部，SARS-CoV-2 的血清流行率合并估计为 15%（95%CI 5-29%），在非洲，合并估计为 6%（95%CI 95% 1-13%）。在美洲，合并估计为 8%（95%CI 95% 6-11%），在欧洲，合并估计为 5%（95%CI 95% 4-6%）。此外，我们还分别分析了其中的三个地区。这项分析估计了研究人群、诊断方法、采样方法、时间、视角和研究类型等亚组中的患病率。

结论

本荟萃分析表明，全球范围内 SARS-CoV-2 的血清流行率在 3%至 15%之间。即使考虑到这一低估计率和全球疫苗接种的增加，仍有许多人易感染 SARS-CoV-2。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/32c055ac88eb/40001_2022_710_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/ed33227db11b/40001_2022_710_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/4cf643ffdbd4/40001_2022_710_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/94efd76dfb63/40001_2022_710_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/df1e0a4766d2/40001_2022_710_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/c3eb50a96562/40001_2022_710_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/b234f6cbf082/40001_2022_710_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/c8453e8f5f45/40001_2022_710_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/32c055ac88eb/40001_2022_710_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/ed33227db11b/40001_2022_710_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/4cf643ffdbd4/40001_2022_710_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/94efd76dfb63/40001_2022_710_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/df1e0a4766d2/40001_2022_710_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/c3eb50a96562/40001_2022_710_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/b234f6cbf082/40001_2022_710_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/c8453e8f5f45/40001_2022_710_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e71/9161479/32c055ac88eb/40001_2022_710_Fig8_HTML.jpg

相似文献

1
SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis.全球范围内 SARS-CoV-2 血清流行率：一项更新的系统评价和荟萃分析。
Eur J Med Res. 2022 Jun 2;27(1):81. doi: 10.1186/s40001-022-00710-2.
2
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
3
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中，如果患者出现以下症状和体征，可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
4
Update on SARS-CoV-2 seroprevalence: regional and worldwide.关于 SARS-CoV-2 血清流行率的最新信息：地区和全球。
Clin Microbiol Infect. 2021 Dec;27(12):1762-1771. doi: 10.1016/j.cmi.2021.09.019. Epub 2021 Sep 25.
5
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.用于 SARS-CoV-2 感染诊断的快速、即时抗原检测。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3.
6
Interventions targeted at women to encourage the uptake of cervical screening.针对女性的干预措施，以鼓励她们接受宫颈癌筛查。
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.
7
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
8
Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: a systematic review and meta-analysis.2020 年 3 月至 2021 年 8 月期间印度 SARS-CoV-2 血清 IgG 抗体的流行率：系统评价和荟萃分析。
Int J Infect Dis. 2022 Mar;116:59-67. doi: 10.1016/j.ijid.2021.12.353. Epub 2021 Dec 28.
9
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
10
Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.工作场所干预措施以降低医疗机构外 SARS-CoV-2 感染的风险。
Cochrane Database Syst Rev. 2022 May 6;5(5):CD015112. doi: 10.1002/14651858.CD015112.pub2.

引用本文的文献

1
SARS-CoV-2 seroprevalence and COVID-19 vaccination coverage in two states of Nigeria from a population based household survey.基于人群的家庭调查得出的尼日利亚两个州的新冠病毒血清流行率和新冠疫苗接种覆盖率
Sci Rep. 2025 Aug 10;15(1):29272. doi: 10.1038/s41598-025-14253-z.
2
Outcomes of the Unvaccinated Geriatric Population with Coronavirus Disease.未接种疫苗的老年新冠患者的结局
Sage Open Aging. 2025 Mar 29;11:30495334251330677. doi: 10.1177/30495334251330677. eCollection 2025 Jan-Dec.
3
Population-based cross-sectional seroprevalence study of SARS-CoV-2 infection in urban residential areas in Ghana.

本文引用的文献

1
SARS-CoV-2 seroprevalence rates of children seeking medical care in Louisiana during the state stay at home order.在路易斯安那州居家令期间寻求医疗护理的儿童中，新冠病毒的血清流行率。
J Clin Virol Plus. 2021 Dec;1(4):100047. doi: 10.1016/j.jcvp.2021.100047. Epub 2021 Nov 14.
2
Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020.2020 年 3 月至 10 月，比利时全国连续前瞻性横断面研究中针对 SARS-CoV-2 的 IgG 抗体血清阳性率-残留样本。
Euro Surveill. 2022 Mar;27(9). doi: 10.2807/1560-7917.ES.2022.27.9.2100419.
3
加纳城市居民区中基于人群的SARS-CoV-2感染横断面血清流行率研究。
BMJ Public Health. 2025 Jun 23;3(1):e001994. doi: 10.1136/bmjph-2024-001994. eCollection 2025.
4
Nationwide seroprevalence of SARS-CoV-2 Delta variant and five Omicron sublineages in companion cats and dogs in the USA: insights into their role in COVID-19 epidemiology.美国伴侣猫和狗中SARS-CoV-2 Delta变异株及五种奥密克戎亚谱系的全国血清流行率：深入了解它们在COVID-19流行病学中的作用。
Emerg Microbes Infect. 2025 Dec;14(1):2437246. doi: 10.1080/22221751.2024.2437246. Epub 2024 Dec 11.
5
Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors: a systematic review and meta-analysis.健康献血者中 SARS-CoV-2 抗体的血清流行率：系统评价和荟萃分析。
BMC Public Health. 2024 Oct 22;24(1):2925. doi: 10.1186/s12889-024-20364-5.
6
COVID-19 IgG seropositivity and its determinants in occupational groups of varying infection risks in two Andean cities of Ecuador before mass vaccination.在厄瓜多尔两个安第斯城市大规模疫苗接种前，不同感染风险职业人群中的 COVID-19 IgG 血清阳性率及其决定因素。
PLoS One. 2024 Aug 29;19(8):e0309466. doi: 10.1371/journal.pone.0309466. eCollection 2024.
7
Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals.镶嵌沙贝科病毒纳米颗粒在预先接种疫苗的动物中引发交叉反应性应答。
Cell. 2024 Oct 3;187(20):5554-5571.e19. doi: 10.1016/j.cell.2024.07.052. Epub 2024 Aug 27.
8
High SARS-CoV-2 Exposure in Rural Southern Mozambique After Four Waves of COVID-19: Community-Based Seroepidemiological Surveys.南非莫桑比克南部农村地区在经历了四波 COVID-19 疫情后，面临着高 SARS-CoV-2 暴露风险：基于社区的血清流行病学调查。
Influenza Other Respir Viruses. 2024 Jun;18(6):e13332. doi: 10.1111/irv.13332.
9
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in HIV-positive and HIV-negative patients in clinical settings in Douala, Cameroon.喀麦隆杜阿拉临床环境中HIV阳性和HIV阴性患者抗SARS-CoV-2 IgG抗体的血清阳性率。
Front Epidemiol. 2023 Aug 14;3:1212220. doi: 10.3389/fepid.2023.1212220. eCollection 2023.
10
Comparing COVID-19 severity in patients hospitalized for community-associated Delta, BA.1 and BA.4/5 variant infection.比较因社区获得性 Delta、BA.1 和 BA.4/5 变异株感染住院的患者的 COVID-19 严重程度。
Front Public Health. 2024 Feb 21;12:1294261. doi: 10.3389/fpubh.2024.1294261. eCollection 2024.
Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.
奥密克戎（B.1.1.529）变异株的出现、显著特征、高全球健康关注以及在持续的 COVID-19 大流行期间应对它的策略。
Environ Res. 2022 Jun;209:112816. doi: 10.1016/j.envres.2022.112816. Epub 2022 Jan 29.
4
Seroprevalence of the SARS-CoV-2 antibody in healthcare workers: a multicentre cross-sectional study in 10 Colombian cities.医护人员中 SARS-CoV-2 抗体的血清流行率：10 个哥伦比亚城市的多中心横断面研究。
Occup Environ Med. 2022 Jun;79(6):388-395. doi: 10.1136/oemed-2021-107487. Epub 2021 Nov 5.
5
Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020.2020 年 3 月至 6 月在 20 个欧洲国家进行的血清学检测和 SARS-CoV-2 血清流行率研究的映射。
J Glob Health. 2021 Jul 31;11:05014. doi: 10.7189/jogh.11.05014. eCollection 2021.
6
Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体的全球血清流行率：一项系统综述和荟萃分析。
PLoS One. 2021 Jun 23;16(6):e0252617. doi: 10.1371/journal.pone.0252617. eCollection 2021.
7
Antibody Responses in COVID-19: A Review.新型冠状病毒肺炎中的抗体反应：综述
Front Immunol. 2021 Apr 15;12:633184. doi: 10.3389/fimmu.2021.633184. eCollection 2021.
8
Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2.理解 SARS-CoV-2 血清流行率研究中的挑战和不确定性。
Int J Environ Res Public Health. 2021 Apr 27;18(9):4640. doi: 10.3390/ijerph18094640.
9
Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies.血清学检测方法比较用于检测 SARS-CoV-2 抗体。
Viruses. 2021 Apr 20;13(4):713. doi: 10.3390/v13040713.
10
Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study.法国癌症中心在首次封锁后对员工和患者进行的 SARS-CoV-2 血清流行率调查：canSEROcov 研究。
Eur J Cancer. 2021 May;148:359-370. doi: 10.1016/j.ejca.2021.02.027. Epub 2021 Feb 27.